Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

A recent review and meta-analysis of semaglutide studies found that this drug can significantly reduce the risk of ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.